Amsurg (AMSG) Tops Q1 EPS by 5c, Raises FY Guidance

Amsurg (NASDAQ: AMSG) reported Q1 EPS of $0.62, $0.05 better than the analyst estimate of $0.57. Revenue for the quarter came in at $570.4 million versus the consensus estimate of $574.3 million.

Amsurg sees FY2015 EPS of $3.31-$3.39, versus prior guidance of $3.24-$3.32 and the consensus of $3.26. Amsurg sees FY2015 revenue of $2.46-2.49 billion, versus prior guidance of $2.44-2.47 billion and the consensus of $2.45 billion. It sees adjusted EBITDA of $454 million to $460 million, up from a range of $445 million to $451 million.

Amsurg sees Q2 2015 EPS of $0.81-$0.84, versus the consensus of $0.84.

For earnings history and earnings-related data on Amsurg (AMSG) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c